View Post Factors That Influence an HIV Coinfected Patient’s Decision to Start Hepatitis C Treatment. AIDS Patient Care and STDs, 23(12): 993-999. In by AHFDecember 16, 2009
View Post Phase 2 Gene Therapy Trial of an Anti-HIV Ribozyme in Autologous CD34+ Cells. Nature Medicine, 15: 285-292. In by AHFMarch 14, 2009
View Post Analysis of a Switch From Enfuvirtide to Raltegravir in Patients with Undetectable Viral Load: Efficacy and Quality of Life at 24 Weeks. Journal of the International Association of Physicians in AIDS Care, 8(2): 85-86. In by AHFMarch 1, 2009
View Post Phase 2 Gene Therapy Trial of an Anti-HIV Ribozyme in Autologous CD34+ Cells. Nature, 15: 285-292. In by AHFFebruary 16, 2009
View Post The Use of Darunavir/Ritonavir as Intensification in Low Viremic HIV-Infected Patients Treated with Boosted Protease Inhibitor-Containing Regimens. Journal of the International Association of Physicians in AIDS Care, 8(1): 21-22. In by AHFFebruary 1, 2009
View Post Rapid HIV Testing in Transgender Communities by Community-Based Organizations in Three Cities. Public Health Reports, 123 (Suppl. 3): 101-114. In by AHFNovember 1, 2008
View Post Meningitis Due to Hematogenous Dissemination of Community-Associated Methicillin-Resistant Staphylococcus aureus (MRSA) in a Patient with AIDS. Journal of the International Association of Physicians in AIDS Care, 7(6): 289-291. In by AHFNovember 1, 2008
View Post No Residual Activity of Raltegravir After Development of 148 Complex Mutations In Vivo. Journal of the International Association of Physicians in AIDS Care, 7(6): 281-282. In by AHFNovember 1, 2008
View Post Service Needs and Factors Related to Quality of Life at Time of Service Enrollment among Persons Living with HIV. Home Health Care Services Quarterly, 18(3): 43-63. In by AHFOctober 16, 2008
View Post Maraviroc for Previously Treated Patients with R5 HIV-1 Infection. The New England Journal of Medicine, 359: 1429-1441. In by AHFOctober 1, 2008
